Global Tumor NGS Detection Market Growth (Status and Outlook) 2023-2029

Global Tumor NGS Detection Market Growth (Status and Outlook) 2023-2029

The global Tumor NGS Detection market size is projected to grow from US$ 1795.1 million in 2022 to US$ 5194.1 million in 2029; it is expected to grow at a CAGR of 16.4% from 2023 to 2029.

United States market for Tumor NGS Detection is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Tumor NGS Detection is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Tumor NGS Detection is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Tumor NGS Detection players cover Agilent, Thermo Fisher Scientific, BGI Group, Roche Foundation Medicine, Sinopharm Group, Fosunpharma, Novogene, Geneseeq and AmoyDx, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

The main purpose of NGS is to discover clinically treatable genetic variants and guide patient treatment.

LPI (LP Information)' newest research report, the “Tumor NGS Detection Industry Forecast” looks at past sales and reviews total world Tumor NGS Detection sales in 2022, providing a comprehensive analysis by region and market sector of projected Tumor NGS Detection sales for 2023 through 2029. With Tumor NGS Detection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Tumor NGS Detection industry.

This Insight Report provides a comprehensive analysis of the global Tumor NGS Detection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Tumor NGS Detection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Tumor NGS Detection market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Tumor NGS Detection and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Tumor NGS Detection.

This report presents a comprehensive overview, market shares, and growth opportunities of Tumor NGS Detection market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Medical Equipment
Consumables

Segmentation by application
Companion Diagnostics
Early Cancer Screening
Drug Discovery
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Agilent
Thermo Fisher Scientific
BGI Group
Roche Foundation Medicine
Sinopharm Group
Fosunpharma
Novogene
Geneseeq
AmoyDx
Burning Rock Medicine
Perkin Elmer
Qiagen NV
Partek
Illumina Inc.
Pacific Biosciences of California Inc.
Life Technologies Corporation
GTH.O
Paradigm Diagnostics
Oxford Nanopore Technologies Ltd.
Eurofins Scientific S.E.

Please note: The report will take approximately 2 business days to prepare and deliver.